Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
As antibiotic resistance increases, there is a need for new therapies to treat infection, particularly in cystic fibrosis (CF), where Pseudomonas aeruginosa is a ubiquitous pathogen associated with increased morbidity and mortality. Bacteriophages are an attractive alternative treatment, as they are specific to the target bacteria and have no documented side effects. The efficacy of phage cocktails was established in vitro. Two P. aeruginosa strains were taken forward into an acute murine infection model with bacteriophage administered either prophylactically, simultaneously, or postinfection. The infective burden and inflammation in bronchoalveolar lavage fluid (BALF) were assessed at various times. With low infective doses, both control mice and those undergoing simultaneous phage treatment cleared P. aeruginosa infection at 48 h, but there were fewer neutrophils in BALF of phage-treated mice (median, 73.2 × 10 4/ml [range, 35.2 to 102.1 × 10 4/ml] versus 174 × 10 4/ml [112.1 to 266.8 × 10 4/ml],P< 0.01 for the clinical strain; median, 122.1 × 10 4/ml [105.4 to 187.4 × 10 4/ml] versus 206 × 10 4/ml [160.1 to 331.6 × 10 4/ml],P< 0.01 for PAO1). With higher infective doses of PAO1, all phage-treated mice cleared P. aeruginosa infection at 24 h, whereas infection persisted in all control mice (median, 1,305 CFU/ml [range, 190 to 4,700 CFU/ml],P< 0.01). Bacteriophage also reduced CFU/ml in BALF when administered postinfection (24 h) and both CFU/ml and inflammatory cells in BALF when administered prophylactically. A reduction in soluble inflammatory cytokine levels in BALF was also demonstrated under different conditions. Bacteriophages are efficacious in reducing both the bacterial load and inflammation in a murine model of P. aeruginosa lung infection. This study provides proof of concept for future clinical trials in patients with CF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development
O'Toole, G. A., & Kolter, R. (1998) · Molecular Microbiology · doi:10.1046/j.1365-2958.1998.01062.x · Cited by 2,697 · cited 1×
“aeruginosa infection whereby originally free-floating (planktonic) organisms switch to a biofilm mode of growth (9).”
BackgroundDispersing biofilms with engineered enzymatic bacteriophage
Lu, T. K., & Collins, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704624104 · Cited by 895
Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase
Hughes, K. A., Sutherland, I. W., & Jones, M. V. (1998) · Microbiology · doi:10.1099/00221287-144-11-3039 · Cited by 360
Cited by
Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32542-3 · Cited by 682
Self-citationRoach, D. R., Leung, C. Y., Henry, M., Morello, E., Singh, D., Di Santo, J. P., Weitz, J. S., & Debarbieux, L. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.06.018 · Cited by 484
Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review
Kakasis, A., & Panitsa, G. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.004 · Cited by 261
Phage therapy for respiratory infections
Chang, R. Y. K., Wallin, M., Lin, Y., Leung, S. S. Y., Wang, H., Morales, S., & Chan, H.-K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.001 · Cited by 207
“[60] assessed the efficacy of a phage cocktail using an acute P.”
BackgroundSelf-citationOoi, M. L., Drilling, A. J., Morales, S., Fong, S., Moraitis, S., Macias-Valle, L., Vreugde, S., Psaltis, A. J., & Wormald, P.-J. (2019) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2019.1191 · Cited by 181
“SNOT-22 scorec 72 (45-95) 29 (26-34) 32 (8-70)”
Self-citationThe applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
“showed that phages were effective in controlling the spreading of infection and can also decrease the bacterial load post-treatment.(66) The combination of antibiotic-phage therapy was used to cure the relapsing periprosthetic joint infection of the knee and chronic osteomyelitis caused by MDR P.”
BackgroundMethodLam, H. Y. P., Lai, M.-J., Wang, P.-C., Wu, W.-J., Chen, L.-K., Fan, H.-W., Tseng, C.-C., Peng, S.-Y., & Chang, K.-C. (2025) · Antibiotics · doi:10.3390/antibiotics14010045 · Cited by 29
“In addition, phage cocktails may also provide a means for reducing the risk of emergent phage resistance [42].”
Metadata
- Authors
- Pabary, R., Singh, C., Morales, S., Bush, A., Alshafi, K., Bilton, D., Alton, E. W. F. W., Smithyman, A., & Davies, J. C.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-02
- Volume
- 60
- Issue
- 2
- Pages
- 744-751
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2268518655
- Cited by
- 100
- References
- 3
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.